Dexamethasone Dosing in Pediatric Patients

Introduction to Dexamethasone Use

• The American Academy of Pediatrics recommends a single dose of dexamethasone 0.6 mg/kg (maximum 16 mg) for all severities of croup 1
• For pediatric patients, dexamethasone dosing is indication-specific: use 0.6 mg/kg (maximum 16 mg) as a single dose for croup and asthma exacerbations, 0.15 mg/kg every 6 hours for 2-4 days for bacterial meningitis, and 6 mg/m² per day for 28 days in acute lymphoblastic leukemia protocols 1, 2, 3

Croup Management

• Oral administration is preferred when the child can tolerate it, as it is equally effective as intramuscular or intravenous routes and avoids injection pain 1
• The clinical duration of action is approximately 24-72 hours, with onset as early as 30 minutes after administration 1
• For severe cases with significant respiratory distress, adjunctive nebulized epinephrine (0.5 mL/kg of 1:1000 solution, maximum 5 mL) can be added while waiting for dexamethasone to take effect 1

Asthma Exacerbations

• For mild to moderate asthma exacerbations, a single dose of dexamethasone 0.6 mg/kg (maximum 16 mg) is equally effective as a 3-5 day course of prednisolone or prednisone 4
• The European Respiratory Review guidelines report consensus on oral corticosteroid dosing: dexamethasone 0.6 mg/kg for 3-5 days, prednisolone 1-2 mg/kg (maximum 40 mg) per 24 hours for 3-5 days, or prednisone 30-50 mg/day for 7 days 4

Bacterial Meningitis

• For H. influenzae type b meningitis in infants and children, the American Academy of Pediatrics recommends dexamethasone 0.15 mg/kg every 6 hours for 2-4 days 2
• Dexamethasone must be initiated 10-20 minutes prior to, or at least concomitant with, the first antimicrobial dose 2
• The Infectious Diseases Society of America suggests that adjunctive dexamethasone should not be given to children who have already received antimicrobial therapy 2

Acute Lymphoblastic Leukemia (ALL)

• The Children's Oncology Group uses a dexamethasone schedule of 6 mg/m² per day for 28 days in certain pediatric ALL protocols 3, 2
• Dexamethasone significantly decreases the risk of isolated CNS relapse and improves event-free survival compared with prednisone 3
• For patients aged 10 years or older, dexamethasone carries a higher risk of osteonecrosis compared to prednisone 2

Bronchopulmonary Dysplasia (BPD)

• High-dose dexamethasone (0.5 mg/kg/day) is not recommended for prevention or treatment of BPD in preterm infants due to adverse neurodevelopmental outcomes 2
• Low-dose dexamethasone therapy (<0.2 mg/kg/day) may facilitate extubation with potentially fewer adverse effects in preterm infants with BPD 2

Common Side Effects and Safety

• Common side effects include gastric irritation, behavioral changes, weight gain, and increased appetite 2
• Age may be an important factor for corticosteroid selection, with dexamethasone showing improved outcomes in patients younger than 10 years for certain conditions 2

Dexamethasone Dosing and Safety in Pediatric Patients

Bronchopulmonary Dysplasia (BPD) in Preterm Infants

• High-dose dexamethasone (0.5 mg/kg/day) is contraindicated for BPD prevention or treatment due to adverse neurodevelopmental outcomes, including neuromotor dysfunction and growth impairment, as recommended by the American Academy of Pediatrics 5, 6, 7
• High-dose dexamethasone (0.5 mg/kg/day) is equivalent to 15-20 mg/kg/day of hydrocortisone, far exceeding safe glucocorticoid exposure, according to the American Academy of Pediatrics 5, 6
• Dexamethasone binds only to glucocorticoid receptors, causing hippocampal neuronal degeneration in animal models, unlike hydrocortisone which binds both mineralocorticoid and glucocorticoid receptors, as noted by the American Academy of Pediatrics 5, 6, 7
• Dexamethasone exposure is linked to decreased hippocampal volume, altered synaptic plasticity, and impaired memory formation, as reported by the American Academy of Pediatrics 5, 6, 7
• Low-dose dexamethasone (<0.2 mg/kg/day) may facilitate extubation with potentially fewer adverse effects, though additional RCTs are needed, according to the American Academy of Pediatrics 7

Dexamethasone Dosing in Pediatric Patients

Chemotherapy-Related Indications

• For antiemetic prophylaxis with moderate-emetic-risk chemotherapy, the American Society of Clinical Oncology recommends 8 mg oral or IV on day 1, combined with a 5-HT3 receptor antagonist 8, 9

Adrenal Insufficiency and Other Indications

• For adrenal insufficiency, the American Academy of Pediatrics suggests 2-3 mg/kg IV/IO (maximum 100 mg) over 3-5 minutes, followed by 1-5 mg/kg every 6 hours for infants or 12.5 mg/m² every 6 hours for older children, and strongly considers concomitant fluid bolus of 20 mL/kg of D5NS or D10NS during the first hour 10
• For immune thrombocytopenia (ITP), the American Society of Hematology suggests prednisone (2-4 mg/kg per day; maximum 120 mg daily for 5-7 days) rather than dexamethasone for children with newly diagnosed ITP due to concerns about higher corticosteroid exposure with repeated dexamethasone courses, although an alternative regimen is 0.6 mg/kg per day (maximum 40 mg per day) for 4 days 11

Age‑Related Recommendations for Dexamethasone Use in Preterm Infants

Contraindications in the First Week of Life

Timing Considerations for Steroid Initiation

Low‑Dose Dexamethasone for Established BPD

Alternative Corticosteroid Strategy

Informed Consent Requirement

Evidence‑Based Recommendations for Pediatric Dexamethasone Use

Perioperative Use (Tonsillectomy) – American Academy of Otolaryngology‑Head and Neck Surgery

• A single intra‑operative intravenous dose of 0.5 mg/kg dexamethasone (studied range 0.15–1.00 mg/kg, maximum 8–25 mg) reduces postoperative nausea/vomiting for up to 24 h, lessens throat pain, and speeds return to oral intake; recommendation based on a randomized controlled trial. 16
• Patients with pre‑existing endocrine disorders receiving exogenous steroids or with diabetes should be excluded because dexamethasone may interfere with glucose‑insulin regulation. 16
• One RCT reported a higher incidence of postoperative hemorrhage as a secondary (unadjusted) outcome after dexamethasone; clinicians should weigh this risk when deciding on prophylaxis. 16

Chemotherapy‑Related Antiemesis – Clinical Oncology Guidelines

• For moderate‑emetic‑risk chemotherapy, adding dexamethasone (≈8 mg oral or IV on day 1; pediatric weight‑based dosing) to a 5‑HT₃ receptor antagonist improves control of nausea and vomiting; the benefit‑risk balance requires careful assessment. (moderate‑quality evidence) 17

Treatment Duration Principles – Hematology Guidelines

• Shorter corticosteroid courses are strongly preferred; extending dexamethasone beyond 7 days increases complications without added benefit (strong recommendation). 18
• In immune thrombocytopenia, prednisone (2–4 mg/kg per day, max 120 mg for 5–7 days) is preferred over dexamethasone (0.6 mg/kg per day, max 40 mg for 4 days) because repeated dexamethasone courses lead to higher overall steroid exposure. (moderate‑quality evidence) 18

High‑Dose Dexamethasone in Infants: Neurodevelopmental Risks and Safer Alternatives

Neurodevelopmental Outcomes of High‑Dose Dexamethasone

• High‑dose dexamethasone (≥0.5 mg/kg/day) used for prevention or treatment of bronchopulmonary dysplasia markedly increases the risk of major neurodevelopmental impairment, including cerebral palsy, lower IQ, and significant disability in treated infants. Evidence from a randomized controlled trial published in Pediatrics (2010) – high‑quality (Level A). 19

• Long‑term follow‑up (age 4–11 years) of the same cohort showed a 36 % incidence of major neurodevelopmental disorder in the dexamethasone group versus 14 % in the placebo group. This difference was statistically significant. Evidence: Pediatrics (2010) – high‑quality (Level A). 20

• Children who received high‑dose dexamethasone exhibited statistically significant reductions in stature, head‑circumference, and IQ scores, and a higher prevalence of significant disability (P = 0.03 for height, P = 0.04 for head‑circumference, P = 0.008 for IQ). Evidence: Pediatrics (2010) – high‑quality (Level A). 19

Pharmacologic Mechanism and Safer Alternative

• Dexamethasone binds exclusively to glucocorticoid receptors, which in animal models leads to hippocampal neuronal degeneration; in contrast, hydrocortisone binds both mineralocorticoid and glucocorticoid receptors and demonstrates a more favorable neurodevelopmental safety profile. Evidence from experimental data reported in Pediatrics (2010). 21

• For prolonged corticosteroid therapy in preterm infants, hydrocortisone is recommended over dexamethasone because of its lower risk of adverse neurodevelopmental effects. Recommendation based on the same 2010 Pediatrics evidence – strong (Grade A). 21